Role of obesity in complicating and confusing the diagnosis and treatment of diabetes in children

Pediatrics

Volumn 121, Issue 2, 2008, Pages 361-368

  Jones, Kenneth Lee ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MC 5103 ^*  (United States)

Author keywords

Insulin resistance; Maturity onset diabetes of the young; Obesity; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT;

CONFUSION; DIABETES MELLITUS; DISEASE CLASSIFICATION; HUMAN; HYPERGLYCEMIA; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; OBESITY;

EID: 38849119173     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-1234     Document Type: Review

References (60)

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: World Health Organization; 2000. WHO technical report series 894
2. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA. 2001;286(22):2845-2848
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States. 1999-2004. JAMA. 2006;295(13):1549-1555
4. Lissau I, Overpeck MD, Ruan WJ, et al. Body mass index and overweight in adolescents in 13 European countries, Israel, and the United States. Arch Pediatr Adolesc Med. 2004;158(1):27-33
5. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA. 1999;282(16):1530-1538
6. National Heart Lung and Blood Institute Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health. Obes Res. 1998;6(suppl 2):51S-209S
7. Thorpe KE, Florence CS, Howard DH, Joski P. Impact of obesity on rising medical spending: Health Tracking 2004 American Diabetes Association Position Statement. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2006;29(suppl 1):S43-S48
8. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985. WHO technical report series 727
9. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787-835
10. Fajans SS. Maturity onset diabetes of the young (MODY). Diabetes Metab Rev. 1989;5(7):579-606
11. Frayling TM, Lindgren CM, Chevre JC, et al. A genome-wide scan in families with maturity-onset diabetes of the young: evidence for further genetic heterogeneity. Diabetes. 2003;52(3):872-881
12. Hattersley AT, Pearson AE. Minireview: pharmacogenetics and beyond - the interaction of therapeutic response, beta cell physiology, and genetics in diabetes. Endocrinology. 2006;147(6):2657-2663
13. Maassen JA, 'T Hart LM, van Essen E, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes. 2004;53(suppl 1):S103-S109
14. Flanagan SE, Edghill AE, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006;49(6):1190-1197
15. Sperling MA. The genetic basis of neonatal diabetes mellitus. Pediatr Endocrinol Rev. 2006;(4 suppl 1):71-75
16. Friedman JE, Dohm GL, Leggett-Frazier CW, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss: effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest. 1992;89(2):701-705
17. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-846
18. Shuldiner AR, Yang R, Gong DW. Resistin, obesity, and insulin resistance: the emerging role of the adipocyte as an endocrine organ. N Engl J Med. 2001;345(18):1345-1346
19. Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des. 2003;9(12):1023-1031
20. Yki-Jarvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med. 2002;95(suppl 42):39-45
21. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88(6):2399-2403
22. Li C, Ford ES, McGuire LC, Mokdad AH, Little RR, Reaven GM. Trends in hyperinsulinemia among nondiabetic adults in the U.S. Diabetes Care. 2006;29(11):396-402
23. Paulson EP, Richenderfer L, Ginsberg-Fellner F. Plasma glucose, free fatty acids, and immunoreactive insulin in sixty-six obese children. Diabetes. 1968;17(5):261-269
24. Glaser N, Jones KL. Non-insulin-dependent diabetes in children and adolescents. Adv Pediatr. 1996;43:359-396
25. Dean H. NIDDM-Y in First Nation children in Canada. Clin Pediatr (Phila). 1998;37(2):89-96
26. Savage PJ, Bennett PH, Senter RG, Miller M. High prevalence of diabetes in young Pima Indians. Diabetes. 1979;28(10):937-942
27. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiological review and a public health perspective. J Pediatr. 2000;136(5):664-672
28. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146(5):693-700
29. Oeltmann JE, Liese AD, Heinze HJ, Addy CL, Mayer-Davis EJ. Prevalence of diagnosed diabetes among African-American and non-Hispanic white youth. Diabetes Care. 2003;26(9):2531-2535
30. Grinstein G, Muzumdar R, Aponte L, Vuguin P, Saenger P, DiMartino-Nardi J. Presentation and 5 year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res. 2003;60(3):121-126
31. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2000;23(3):381-390
32. Phillips SA, Jones KL. Type 2 diabetes in children and adolescents. In: Daneman D, Hamilton J, eds. Insulin Resistance in Children and Adolescents. Huppauge, NY: Nova Science Publishers, Inc.; 2005:121-162
33. Jones KL, Eisenbarth G, Klingensmith G, Fiedorek FT. Comparison of type 1 marker positive and negative children referred with presumptive type 2 diabetes. In: Proceedings of the 84th Annual Endocrine Society Meeting. P2-357, 2002:404
34. Vähäsalo P, Knip M, Karjalainen J, Tuomilehto-Wolf E, Lounamaa R, Akerblom HK. The Childhood Diabetes in Finland Study Group: islet cell-specific autoantibodies in children with insulin-dependent diabetes mellitus and their siblings at clinical manifestation of the disease. Eur J Endocrinol. 1996;135(6):689-696
35. Jones KL, Arslanian S, Peterokova VA, Park J-S, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25(1):89-94
36. Sabbah E, Savola K, Ebeling T, et al. Genetic, autoimmune and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care. 2000;23(9):1326-1332
37. Falorni A, Gambelunghe G, Forini F, et al. Autoantibody recognition of COOH terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab. 2000;85(1):309-613
38. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997;350(9087):1288-1293
39. Castleden HAJ, Shields B, Bingley PJ, et al. GAD antibodies in probands and their relatives in a cohort clinically selected for type 2 diabetes. Diabet Med. 2006;23(8):834-838
40. Hathout EH, Thomas W, El-Shahaway M, et al. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics. 2001;107(6). Available at: www.pediatrics.org/cgi/content/full/107/6/e102
41. Palmer JP, Hirsch IB. What's in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care. 2003;26(2):536-538
42. Gilliam LK, Brooks-Worrell BM, Palmer JP, Greenbaum CJ, Pihoker C. Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. J Autoimmun. 2005;25(3):244-250
43. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes: "double" diabetes. Pediatr Diabetes. 2003;4(2):110-113
44. Kibirige M, Metcalf B, Renuja R, Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care. 2003;26(10):2865-2870
45. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44(7):914-922
46. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev. 2002;18(3):192-200
47. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia. 2004;47(10):1661-1667
48. Dabelea D, D'Agostino RB Jr, Mayer-Davis EJ, et al. Testing the accelerator hypothesis: body size, beta-cell function, and age of onset of type 1 (autoimmune) diabetes. Diabetes Care. 2006;29(2):290-294
49. Kahn SE, Prigeon RL, McCulloch DK. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993;42(11):1663-1672
50. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance. Diabetes Care. 2003;26(1):138-143
51. Särnblad S, Kroon M, Åman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323-329
52. Coscelli C, Palmari V, Saccardi F, Alpi O, Bonora E. Evidence that metformin addition to insulin induces an amelioration of glycaemic profile in type 1 (insulin-dependent) diabetes mellitus. Curr Ther Res. 1984;35(6):1058-1064
53. Janssen M, Rillaerts E, De Leeuw I. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother. 1991;45(8):363-367
54. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care. 2005;28(7):1562-1567
55. Zdravkovic V, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr. 2006;149(6):845-849
56. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471
57. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic patients. J Clin Endocrinol Metab. 2006;91(9):3349-3354
58. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467-477
59. Maassen JA, 'T Hart LM, van Essen E, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes. 2004;53(suppl 1):S103-S109
60. Clemons D, Gottschalk ME, Jones KL. Basal and post prandial C-peptide values in a racially mixed population of adolescents with type 2 diabetes mellitus. Diabetes. 1999;48(suppl 1):80A